Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients
ObjectiveTo estimate the cost-effectiveness of adding serplulimab to chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC) patients in a first-line setting from a Chinese perspective.MethodsA three-health state partitioned survival model was constructed to simulate disease developm...
Sparad:
| Huvudupphov: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2024-04-01
|
| Serie: | Frontiers in Immunology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1382088/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|